Logo image of LABS.CA

MEDIPHARM LABS CORP (LABS.CA) Stock Fundamental Analysis

TSX:LABS - Toronto Stock Exchange - CA58504D1006 - Common Stock - Currency: CAD

0.065  -0.01 (-7.14%)

Fundamental Rating

3

Taking everything into account, LABS scores 3 out of 10 in our fundamental rating. LABS was compared to 35 industry peers in the Pharmaceuticals industry. The financial health of LABS is average, but there are quite some concerns on its profitability. While showing a medium growth rate, LABS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LABS had negative earnings in the past year.
LABS had a negative operating cash flow in the past year.
In the past 5 years LABS always reported negative net income.
LABS had a negative operating cash flow in each of the past 5 years.
LABS.CA Yearly Net Income VS EBIT VS OCF VS FCFLABS.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -14.35%, LABS is not doing good in the industry: 65.71% of the companies in the same industry are doing better.
LABS's Return On Equity of -17.28% is in line compared to the rest of the industry. LABS outperforms 57.14% of its industry peers.
Industry RankSector Rank
ROA -14.35%
ROE -17.28%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-40.33%
ROE(3y)-34.34%
ROE(5y)-50.73%
ROIC(3y)N/A
ROIC(5y)N/A
LABS.CA Yearly ROA, ROE, ROICLABS.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60 -80

1.3 Margins

LABS's Gross Margin of 30.31% is in line compared to the rest of the industry. LABS outperforms 57.14% of its industry peers.
LABS's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-3.36%
LABS.CA Yearly Profit, Operating, Gross MarginsLABS.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

More info and screens

5

2. Health

2.1 Basic Checks

LABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LABS has more shares outstanding
Compared to 5 years ago, LABS has more shares outstanding
LABS has a better debt/assets ratio than last year.
LABS.CA Yearly Shares OutstandingLABS.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
LABS.CA Yearly Total Debt VS Total AssetsLABS.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

LABS has an Altman-Z score of -1.59. This is a bad value and indicates that LABS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of LABS (-1.59) is worse than 62.86% of its industry peers.
LABS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of LABS (0.00) is better than 88.57% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.59
ROIC/WACCN/A
WACC9.35%
LABS.CA Yearly LT Debt VS Equity VS FCFLABS.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

LABS has a Current Ratio of 3.61. This indicates that LABS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.61, LABS belongs to the top of the industry, outperforming 91.43% of the companies in the same industry.
A Quick Ratio of 2.41 indicates that LABS has no problem at all paying its short term obligations.
LABS's Quick ratio of 2.41 is amongst the best of the industry. LABS outperforms 85.71% of its industry peers.
Industry RankSector Rank
Current Ratio 3.61
Quick Ratio 2.41
LABS.CA Yearly Current Assets VS Current LiabilitesLABS.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

LABS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.50%, which is quite impressive.
Looking at the last year, LABS shows a quite strong growth in Revenue. The Revenue has grown by 16.23% in the last year.
The Revenue for LABS have been decreasing by -20.15% on average. This is quite bad
EPS 1Y (TTM)22.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
Revenue 1Y (TTM)16.23%
Revenue growth 3Y24.58%
Revenue growth 5Y-20.15%
Sales Q2Q%10.59%

3.2 Future

LABS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.42% yearly.
LABS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.57% yearly.
EPS Next Y74.5%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year13.37%
Revenue Next 2Y14.57%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LABS.CA Yearly Revenue VS EstimatesLABS.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M 100M
LABS.CA Yearly EPS VS EstimatesLABS.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 -0.1 -0.2 -0.3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LABS. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LABS.CA Price Earnings VS Forward Price EarningsLABS.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LABS.CA Per share dataLABS.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04 0.06 0.08 0.1

4.3 Compensation for Growth

A more expensive valuation may be justified as LABS's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

LABS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEDIPHARM LABS CORP

TSX:LABS (8/1/2025, 7:00:00 PM)

0.065

-0.01 (-7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)08-18 2025-08-18
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners6.71%
Ins Owner ChangeN/A
Market Cap27.35M
Analysts42.22
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.41%
Min Revenue beat(2)0.49%
Max Revenue beat(2)8.33%
Revenue beat(4)2
Avg Revenue beat(4)-3.45%
Min Revenue beat(4)-21.53%
Max Revenue beat(4)8.33%
Revenue beat(8)4
Avg Revenue beat(8)-7.37%
Revenue beat(12)5
Avg Revenue beat(12)-4.06%
Revenue beat(16)5
Avg Revenue beat(16)-7.23%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)33.33%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.64
P/FCF N/A
P/OCF N/A
P/B 0.63
P/tB 0.64
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0.1
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.35%
ROE -17.28%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.31%
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-40.33%
ROE(3y)-34.34%
ROE(5y)-50.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-3.36%
F-Score6
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.83%
Cap/Sales 0.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.61
Quick Ratio 2.41
Altman-Z -1.59
F-Score6
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)27.57%
Cap/Sales(3y)1.89%
Cap/Sales(5y)6.02%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%90%
EPS Next Y74.5%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.23%
Revenue growth 3Y24.58%
Revenue growth 5Y-20.15%
Sales Q2Q%10.59%
Revenue Next Year13.37%
Revenue Next 2Y14.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y57.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y54.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y53.05%
OCF growth 3YN/A
OCF growth 5YN/A